B-cell Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation [Phase 1]
This Phase 1 trial evaluated donor-derived anti-CD19 CAR-T cells in patients with recurrent or persistent B-cell malignancies after allogene…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: CD22 Redirected Autologous T Cells for ALL [Phase 1]
Phase 1 clinical trial update on autologous T cells redirected to CD22 for B-cell leukemias and lymphomas, sponsored by the University of Pe…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. [Phase 4]
This Phase 4 trial update describes extending ibrutinib treatment for patients who continue to benefit from the therapy.
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies [Phase 2]
This update announces the completion of a Phase 2 trial evaluating CD19-CAR-T2 cells for CD19-positive B-cell malignancies, including B-cell…
-
CLINICAL_TRIALS trial_result · 2023-07-11Clinical Trial Update: A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 study evaluating a novel anti-CD19 CAR-T therapy in patients with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial updating CAR-T therapy targeting CD19 and CD22 for relapsed/refractory B-cell leukemia and lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-10-20Clinical Trial Update: CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy [Phase 2]
Phase 2 trial update of CD19-targeting, 3rd generation CAR T cells for refractory B-cell malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2021-02-10Clinical Trial Update: Induced-T Cell Like NK Cells for B Cell Malignancies [Phase 1, Phase 2]
A clinical trial update for induced-T cell like NK cells targeting B cell malignancies is underway in Phase 1/Phase 2, with unspecified curr…
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma [Phase 1, Phase 2]
Phase I/IIA study of CART19 cells in chemotherapy-resistant or refractory CD19+ leukemia and lymphoma completed; results posted.
-
CLINICAL_TRIALS trial_result · 2018-03-13Clinical Trial Update: A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia [Phase 1]
This clinical trial update covers a Phase 1 feasibility and safety study evaluating concomitant therapy with allogeneic CAR-T cells and allo…
-
CLINICAL_TRIALS trial_result · 2018-01-16Clinical Trial Update: A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]
A feasibility and safety study evaluating universal dual-specificity CAR-T cells targeting CD19/CD20 or CD22 for relapsed or refractory B ce…
-
CLINICAL_TRIALS trial_result · 2017-10-30Clinical Trial Update: CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. [Phase 1, Phase 2]
A Phase I/IIa trial evaluating CD19-targeting third-generation CAR T cells for refractory B-cell malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2016-10-14Clinical Trial Update: CD19-redirected Autologous Cells (CAR-CD19 T Cells) [Phase 1]
Phase 1 clinical trial update on autologous CAR-CD19 T cells targeting CD19-positive malignant B-cell leukemia and lymphoma.
-
CLINICAL_TRIALS trial_result · 2016-01-01Clinical Trial Update: Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia [Phase 1, Phase 2]
This clinical trial update describes an autologous CD19-directed CAR-T cell therapy for recurrent or refractory B-cell leukemia in Phase 1/2…
-
CLINICAL_TRIALS trial_result · 2013-05-22Clinical Trial Update: Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma [Phase 1]
Phase 1 study assessing the safety and tolerability of PCI-32765 (ibrutinib) in patients with recurrent B-cell lymphoma or B-cell leukemia; …